Aim: To compare the adverse effects profile of Travoprost vs Brimonidine/Timolol in patients of Primary Open Angle Glaucoma(POAG) Methodology: In this randomized open label 12-week study, 70 patients were randomized to receive either 0.004% of Travoprost once daily in the evening or Brimonidine/Timolol combination twice daily. Their safety was concluded by monitoring their adverse effects during follow-up visits at 2, 4, 8, and 12 weeks. Results: Both treatment regimens were well tolerated during the period of study. Patients in the Travoprost group had a higher incidence of ocular irritation (30%), pigmentation of skin (33%), Thickening of eyelashes (39%) and hyperemia (36%) when compared to the Brimonidine/Timolol group which showed only ocular irritation (21%) and foreign body sensations (28%). Conclusions: The incidence of adverse effects were not significantly different between Travoprost and Brimonidine/Timolol therapy. Both had favourable safety profiles. However, Travoprost had more local side effects profile when compared to Brimonidine/Timolol.